Frederick Kitaka
Frederick Mutebi Kitaka, is a Ugandan physicist, mathematician, accountant, entrepreneur, and industrialist. He is the executive director of finance at Quality Chemical Industries Limited, a Ugandan limited liability company. QCIL is the only Sub-Saharan pharmaceutical company that is licensed to manufacture triple therapy antiretroviral medication. He is also a shareholder in the company and sits on its board of directors.
His expertise in financial planning and management, economic policy, investment management, and corporate governance has positioned him as a leading figure in his field. Mutebi Kitaka's commitment to societal improvement through his philanthropic efforts further highlights his multifaceted impact on his community and beyond.
Early life and education
He was born in Uganda in August 1962. He is the son of the late Fancis Xavier Kitaka, the first Ugandan to qualify as a biochemist and one of the four co-founders of Quality Chemical Industries Limited.Mutebi Kitaka was educated at St. Mary's College Kisubi, a distinguished boys-only Catholic high school located in Wakiso District in the Buganda Region of Uganda. He was then admitted to Makerere University, Ugaanda's largest and oldest public university, where he studied mathematics and physics, graduating with a Bachelor of Science degree. Later, he studied at the University of Buckingham in the United Kingdom, graduating with a BSc degree in Accounting and Finance.
Work history
From 1994 until 1997, Mutebi Kitaka worked as the financial controller at Coopers Uganda Limited, a company that later rebranded to MTK Holdings Limited. In 1997, Mutebi Kitaka co-founded Quality Chemicals Limited, where he served as Chief Finance Officer. The company specialized in distributing human, veterinary, and agrochemical products, marking the beginning of his illustrious career in the pharmaceutical industry.In 2005, he elevated his entrepreneurial journey by co-founding Cipla Quality Chemical Industries Limited, a pharmaceutical manufacturing plant renowned for producing high-quality WHO pre-qualified treatments for HIV/AIDS, Malaria, and Hepatitis B. Under his leadership, the company achieved a significant milestone with a successful IPO in 2018, valuing it at USD255 million.